Conclusion
The role of Aspirin did not reduce the risk of cardiovascular events and
has been considered with low risk for primary prevention of
cardiovascular events. However, the present meta-analysis reported no
significant risk of Aspirin in the primary prevention of cardiovascular
events when compared with placebo in diabetic patients. In addition, we
found no significant risk of Aspirin on the primary endpoints of
cardiovascular events and cardiovascular mortality over the risk of
bleeding outcomes in diabetic patients. However, further investigations
of Aspirin combined with other antiplatelet drugs can be conducted to
rule out the possible advantages in preventing cardiovascular risk among
patients of diabetes.